The AEs that led to treatment withdrawal were “ALT, AST increased (n = 1)”, “Eczema (n = 1)”, and “Polyarthritis (n = 1)” in the topiroxostat group, and “Acute hepatitis (n = 1)” in the placebo group. The gene discussed is GPT; the disease is Acute hepatitis.